$21 billion! Gilead's acquisition of Immunomedics will include "first-in-class" antibody consuming drugs into the pocket.

Gilead Sciences announced a final deal with U.S. biotech company Immunomedics (Nasdaq: IMMU) to buy Immunomedics for $88 a share in cash, totalling about $21 billion, in a deal expected to close in the fourth quarter of 2020.
the acquisition, Gilead will expand its cancer product pipeline again and acquire the "first-in-class" antibody conceding drug Trodelvy (sacituzumab govitecan-hziy) targeted by Immunomedics. ), the drug was approved by the FDA on April 22 this year for third-line treatment for adult patients with metastasis triple negative breast cancer (mTNBC) who had received at least two therapies in the past, after obtaining accelerated approval, priority review, breakthrough therapy identification, and fast-track drug review.
Trodelvy is the FDA-approved antibody concedes drug for the treatment of triple-yin breast cancer, and the first approved antibody conceding drug targeting human nourishment layer cell surface antigen 2 (Trop-2), consisting of an antibody targeting TROP-2, Sacituzumab, and the active metabolite SN-38 of the toxin drug iricannote (CL2A).
Trap-2 is expressed in large quantities on the surface of many tumor cells, such as breast cancer, cervical cancer, colorectal cancer, and less in normal tissues.
in triple-negative breast cancer, the Trop-2 expression rate reached 90%, so Trodelvy can target SN-38 to the solid tumor lesions through Sacituzumab, playing a chemically toxic killing role.
it is understood that detailed results of asCENT, a clinical trial on Trodelvy's treatment of late-stage mTNBC3, are expected to be presented at this year's virtual meeting of the European Society of Oncology (ESMO), in addition to data on Trodelvy's treatment of patients with HR-/HER2-breast cancer as a third-line therapy and other solid tumors such as bladder cancer in registered Phase 2 clinical trials.
, Immunomedics plans to file a Supplementary Biologics Licensing Application (sBLA) in the fourth quarter of this year to support Trodelvy's full FDA approval.
acquisition follows Gilead's $11.9 billion acquisition of CAR-T company Kite Pharma in March 2017 and fortySeven, a pioneer of CD47 antibody drugs, for $4.9 billion in March 2020. After buying a 49.9 percent stake in cancer immunotherapy company Pionyr for $275 million and tidal 49.9 percent of cancer immunotherapy company Tizona for $300 million in July, it's another big deal for cancer.
press release notes that Trodelvy will bring a cornerstone product to Gilead Sciences, broadening and deepening the company's solid tumor pipeline, while insiders predict global sales of Trodelvy could reach $1.44 billion by 2024.
at home, Trodelvy's interest is owned by Everest Pharmaceuticals, a late-clinical biopharmaceutical company.
May 2019, Yunding Xinyao and Immunomedics reached an exclusive license agreement of $835 million for Trodelvy's development and promotion interests in Greater China, South Korea and a number of other countries and regions in South Asia.
currently plans to conduct bridge-registered trials of mTNBC third-line treatment, registered trials of third-line treatment of HR-HER2-metastatic breast cancer (mBC), registration trials of second/third-line treatment of metastatic urethra cell carcinoma, and Asian basket trials in 2020-2021.
addition, Yunding Xinyao plans to submit a listing application for the product in China by the end of 2021 or the first half of 2022.
In addition, domestic Colum Pharmaceuticals, Baiotai, Junshi Bio, Cady Bio and other enterprises are also in the Trap-2 antibody European Union drug layout, the current Colum pharmaceutical industry has entered Phase II clinical, other enterprises in Phase I.
source: Medical Valley.com!-- content presentation ends -- !-- to determine whether the login ends.